946 related articles for article (PubMed ID: 32687917)
21. COVID-19: The Immune Responses and Clinical Therapy Candidates.
Zhand S; Saghaeian Jazi M; Mohammadi S; Tarighati Rasekhi R; Rostamian G; Kalani MR; Rostamian A; George J; Douglas MW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756480
[TBL] [Abstract][Full Text] [Related]
22. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
Ahlawat S; Asha ; Sharma KK
Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
24. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
26. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
27. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.
Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY
J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230
[TBL] [Abstract][Full Text] [Related]
28. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
30. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
31. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
32. Neurological Damage by Coronaviruses: A Catastrophe in the Queue!
Mishra R; Banerjea AC
Front Immunol; 2020; 11():565521. PubMed ID: 33013930
[TBL] [Abstract][Full Text] [Related]
33. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K
Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401
[TBL] [Abstract][Full Text] [Related]
34. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
35. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
[TBL] [Abstract][Full Text] [Related]
37. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L; Lacal PM; Barbaccia ML; Graziani G
Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
[TBL] [Abstract][Full Text] [Related]
38. [What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019].
Liu YJ; Yang YL; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Apr; 43(4):339-344. PubMed ID: 32294817
[TBL] [Abstract][Full Text] [Related]
39. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
Abid MB; Mughal M; Abid MA
JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
[No Abstract] [Full Text] [Related]
40. Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2.
Pamukçu B
Anatol J Cardiol; 2020 Oct; 24(4):224-234. PubMed ID: 33001051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
